Table 1. Baseline Characteristics by Study Group among Kidney Transplant Recipients in FAVORIT*.
| Range | Random Sub-cohort | CVD Event cases | Death cases |
|---|---|---|---|
| N | 513 | 300 | 371 |
| Age ± SD | 51 ± 9 | 55 ± 9 | 56 ± 10 |
| Female, n (%) | 197 (38%) | 103 (34%) | 136 (37%) |
| Race | |||
| White | 386 (76%) | 226 (75%) | 269 (73%) |
| Black | 86 (17%) | 54 (18%) | 76 (21%) |
| Other | 38 (7%) | 20 (7%) | 26 (7%) |
| Treatment group | |||
| High dose vitamin | 257 (50%) | 147 (49%) | 183 (49%) |
| Low dose vitamin | 256 (50%) | 153 (51%) | 188 (51%) |
| Country, n (%) | |||
| US | 351 (68%) | 239 (80%) | 298 (80%) |
| Canada | 70 (14%) | 38 (12%) | 37 (10%) |
| Brazil | 92 (18%) | 23 (8%) | 36 (10%) |
| Graft vintage, median [IQR] | 3.90 [1.72, 7.25] | 4.47 [1.89, 7.88] | 4.42 [1.76, 7.89] |
| Living donor kidney, n (%) | 212 (41%) | 99 (33%) | 106 (29%) |
| Calcineurin inhibitor use, n (%) | 429 (88%) | 265 (91%) | 316 (88%) |
| Sirolimus use, n (%) | 53 (10%) | 25 (8%) | 41 (11%) |
| CVD at baseline, n (%) | 96 (19%) | 124 (41%) | 126 (34%) |
| Diabetes, n (%) | 189 (37%) | 193 (64%) | 216 (58%) |
| Smoking, n (%) | |||
| Never | 254 (50%) | 133 (44%) | 142 (38%) |
| Current | 61 (12%) | 41 (14%) | 53 (14%) |
| Past | 192 (37%) | 125 (42%) | 174 (47%) |
| Body mass index (kg/m2) ± SD | 29.0 ± 5.9 | 29.7 ± 6.4 | 29.5 ± 6.4 |
| SBP (mmHg) ± SD | 136 ± 20 | 143 ± 21 | 141 ± 20 |
| DBP (mmHg) ± SD | 79 ± 12 | 78 ± 12 | 77 ± 12 |
| LDL cholesterol (mg/dl) ± SD | 104 ± 33 | 98 ± 37 | 99 ± 37 |
| HDL cholesterol (mg/dl) ± SD | 47 ±14 | 45 ± 14 | 45 ±15 |
| eGFR (ml/min/1.73m2) ± SD | 46 ± 18 | 44 ± 18 | 45 ± 18 |
| Urine ACR (mg/g), median [IQR] | 24.7 [9.6, 106.4] | 46.4 [13.6, 238.6] | 58.0 [15.0, 240.3] |
| Urine NGAL (ng/ml), median [IQR] | 20.2 [8.2, 50.4] | 25.0 [10.7, 60.5] | 28.8 [13.5, 80.9] |
| Urine IL 18 (pg/ml), median [IQR] | 28.8 [11.5,60.5] | 28.9 [11.2, 60.6] | 34.0 [14.0, 80.8] |
| Urine KIM-1 (pg/ml), median [IQR] | 653.0 [310.9, 1363.2] | 746.0 [353.3, 1668.7] | 941.6 [430.8, 1764.9] |
| Urine L FABP (ng/ml), median [IQR] | 6.1 [3.0, 17.6] | 7.8 [3.7, 22.6] | 8.2 [3.8, 24.7] |
| Urine α1 microglobulin (mg/dl), median [IQR] | 1.6 [0.8, 3.7] | 2.3 [1.1, 4.6] | 2.4 [1.2, 5.0] |
| Urine MCP-1 (pg/ml), median [IQR] | 178.2 [83.8, 349.2] | 218.0 [84.7, 448.5] | 234.9 [108.2, 466.8] |
| Urine PINP (mcg/L), median [IQR] | 2.3 [1.2, 3.8] | 2.4 [1.2, 4.0] | 2.4 [1.3, 4.0] |
| Urine PIIINP (mcg/L), median [IQR] | 3.5 [2.1, 6.0] | 3.8 [2.0, 6.2] | 3.7 [1.9, 6.3] |
CVD = cardiovascular disease; SBP = systolic blood pressure; DBP = diastolic blood pressure; LDL = low-density lipoprotein; HDL = high-density lipoprotein; eGFR = estimated glomerular filtration rate; ACR = albumin to creatinine ratio